OLMA News and Press, Olema Pharmaceuticals Inc. From 12/08/21

Energy Focus (NASDAQ:EFOI) +52% launches nUVo virus-targeted UVC air disinfectors to public. Lexaria Bioscience (NASDAQ:LEXX) +25% dehydraTECHTM-CBD reduces arterial stiffness, results confirmed in human clinical study HYPER-H21-2. Dare Bioscience (NASDAQ:DARE) +23% announces F...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks closed out the week with a decline, but managed to limit some damage with last-hour buying. The Nasdaq (COMP.IND) -1.9% took the brunt...

Olema Pharmaceuticals' (OLMA +10.2%) director BVF Partners has purchased 739,675 shares at $9.39/share. The total transaction values at $6.9M. SEC Filing. The company's 51.31% shareholdings are held by institutions: Earlier, As Olema falls 60% following data confusion, Street analysts re...

Omicron and the Federal Reserve combined to send stocks reeling on Tuesday, with the S&P dropping by nearly 2%. Department store chains exemplified the slide, with the added catalyst of a Sell rating for one of the industry's biggest players. Dillard's (NYSE:DDS) lost nearly a fifth of it...

Although shares of Olema Pharmaceuticals (NASDAQ:OLMA) fell 60% in trading today, two Street analysts remain bullish on the company's prospects. The plunge was precipitated by what Olema called a "falsified poster" released on social media yesterday afternoon dealing with early-stage data on ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Adagio Therapeutics (NASDAQ: ADGI ) stock is rising higher on Tuesday as investors on social media can’t stop talking about the company. Source: Shutterstock Interest in ADGI stock is trending higher to...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Guardforce AI (NASDAQ: GFAI ) stock is running higher on Tuesday thanks to news of a deal with Hadyai CCC in Thailand. Source: Shutterstock.com This deal has Guardforce Cash Solutions Security, a subsidiary of...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Olema Pharmaceuticals (NASDAQ: OLMA ) stock isn’t doing so hot on Tuesday following the release of results from a Phase 1/2 clinical trial. Source: Shutterstock According to a press release , Olema Pha...

Olema Pharmaceuticals (NASDAQ:OLMA)announced that three patients experienced a reduction in the tumor size (partial responses) out of 24 efficacy-evaluable patients in its ongoing Phase 1/2 clinical trial for OP-1250 against metastatic breast cancer and other women’s cancers. As of Nov...

Successful completion of dose-escalation stage of ongoing Phase 1/2 clinical study; OP-1250 demonstrated highly attractive pharmacokinetics, favorable tolerability, and clear efficacy signals Robust anti-tumor activity, including three partial responses (two confirmed and one ...